{
    "clinical_study": {
        "@rank": "127762", 
        "arm_group": [
            {
                "arm_group_label": "Naftopidil dose 2", 
                "arm_group_type": "Experimental", 
                "description": "PO administration"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "PO administration"
            }, 
            {
                "arm_group_label": "Naftopidil dose 1", 
                "arm_group_type": "Experimental", 
                "description": "PO administration"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the efficacy and safety of Naftopidil in Korean male\n      patients with with lower urinary tract symptoms associated with benign prostatic\n      hyperplasia.\n\n      The investigators hypothesized that Naftopidil which came onto marcket in Japan would effect\n      in improvement of voiding and storage difficulty.\n\n      Design:\n\n      Placebo-controlled, Randomized, Double-blind, Double-dummy, Parallel group, Fixed dose\n      design"
        }, 
        "brief_title": "Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male patients aged 4 years or more diagnosed with BPH\n\n        Exclusion Criteria:\n\n          -  subjects with uncontrolled blood pressure\n\n          -  subjects with hepatic or renal dysfunction\n\n          -  subjects with prostate cancer\n\n          -  Had treatments for BPH using other alpha receptor antagonists within 2 weeks"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "411", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922375", 
            "org_study_id": "FLV_BPH_IV-1"
        }, 
        "intervention": {
            "arm_group_label": [
                "Naftopidil dose 2", 
                "Naftopidil dose 1"
            ], 
            "intervention_name": "Naftopidil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Naftopidil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gwangju", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Chonnam national university hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia", 
        "overall_official": [
            {
                "affiliation": "Seoul St. Mary's Hospital", 
                "last_name": "Sae-Woong Kim, MD.PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gyeongsang National University Hospital", 
                "last_name": "Jae-Seok Hyun, Md, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Guro Hospital", 
                "last_name": "Du-Geon Moon, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pusan National University Hospital", 
                "last_name": "Nam-Cheol Park, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Samsung Medical Center", 
                "last_name": "Sung-Won Lee, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Soo-Woong Kim, Md, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Tai-Young Ahn, Md, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Yeongnam University Hospital", 
                "last_name": "Ki-Hak Moon, Md, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ewha Womans University Hospital", 
                "last_name": "Woo-Sik Chung, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University", 
                "last_name": "Kweon-Sik Min, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonbuk National University Hospital", 
                "last_name": "Jong Kwan Park, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kangdong Sacred Heart Hospital", 
                "last_name": "Dae Yul Yang Yang, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inha University Hospital", 
                "last_name": "Ji- Kan Ryu, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Efficacy(IPSS score change)", 
            "safety_issue": "No", 
            "time_frame": "From 0 week(baseline) to 12 week(end of the treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922375"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Efficacy(IPSS, Uroflowmetry parameter, LUTS-GAQ)", 
            "safety_issue": "No", 
            "time_frame": "From 0 week(baseline) to 12 week(end of the treatment)"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}